Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DAPTACEL + IPOL + ActHIB
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination immunization regimen consisting of three separate vaccines: DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), IPOL (Inactivated Poliovirus Vaccine), and ActHIB (Haemophilus b Conjugate Vaccine). Developed and manufactured by Sanofi Pasteur, this regimen provides active immunization against five pediatric diseases: diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease caused by Haemophilus influenzae type b. DAPTACEL is a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids. IPOL is a trivalent inactivated poliovirus vaccine containing types 1, 2, and 3. ActHIB is a conjugate vaccine consisting of the Haemophilus influenzae type b capsular polysaccharide (PRP) covalently bound to tetanus toxoid. In clinical development, this separate-injection schedule served as the reference standard to evaluate the safety and immunogenicity of the pentavalent combination vaccine, Pentacel.
- Brand names
- DAPTACELIPOLActHIB
- Other names
- DTaP + IPV + HibDiphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed + Inactivated Poliovirus Vaccine + Haemophilus b Conjugate Vaccine
02
Targets
PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on DAPTACEL + IPOL + ActHIB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAPTACEL + IPOL + ActHIB.